PHARMATHENE (Stock Symbol: PIP)
PIP- Stock Profile
|Stock Ticker (Symbol):||PIP|
|Traded Exchange:||Amex Stock Exchange|
|Average Traded Price:||$1.69|
|Average Daily Traded Volume:||214,600|
|Started to Trade on:||Friday, July 01, 2011|
PharmAthene, Inc., a biodefense company, together with its subsidiaries, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. Its product candidates include SparVax, a recombinant protective antigen (rPA) anthrax vaccine to protect against inhalation anthrax that has completed one Phase I and two Phase II clinical trials; and Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax, which has completed Phase I clinical trial. The company's product candidates also include Protexia, a recombinant enzyme (butyrylcholinesterase), which mimics a natural bioscavenger for the prevention or treatment of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. In addition, its product candidates include RypVax, a recombinant plague vaccine comprising separate recombinant F1 (rF1) and V (rV) antigens produced in Escherichia coli, which completed three Phase I human clinical trials; and rPA anthrax vaccine, which does not require refrigeration. The company's customers include National Institute of Allergy and Infectious Diseases, the U.S. Department of Defense, Biomedical Advanced Research and Development Authority, and the U.S. National Institutes of Health. It has a collaboration agreement with Medarex, Inc. to develop and commercialize Valortim. PharmAthene, Inc. was founded in 2001 and is based in Annapolis, Maryland.